The five-year plan was launched during the CPRIT 2026 Innovations Conference in Galveston this month. Photo via Unsplash.com

MD Anderson, on behalf of a coalition of health systems, has announced a new plan to eliminate cervical cancer in Texas.

The five-year Texas Lone Star Cervical Cancer Elimination Plan was launched during the Cancer Prevention and Research Institute of Texas (CPRIT) 2026 Innovations Conference in Galveston this month.

The plan focuses on three major pillars with goals to be achieved by 2032:

  • HPV vaccination: Increase the percentage of Texas boys and girls up to date on human papillomavirus (HPV) vaccination by age 15 from 50.5 percent to 80 percent
  • Cervical cancer screening: Raise the share of Texas women up to date on cervical cancer screening from 64 percent to 80 percent
  • Timely follow-up, diagnosis and treatment: Ensure 80 percent of women receive diagnostic follow-up and treatment when needed through community outreach, patient navigation, provider training and survivorship support

Overall, the coalition wants to see fewer than four new cases of cervical cancer annually per 100,000 Texas women by 2032, according to a news release from MD Anderson. Currently, Texas has an incidence rate of 9.5 women per 100,000 diagnosed with cervical cancer, compared with 7.5 women per 100,000 nationally.

“Texas has the tools to prevent nearly every case of cervical cancer, but tools can save lives only when people can utilize them,” Dr. Ernest Hawk, vice president and division head of Cancer Prevention and Population Sciences at MD Anderson, said in the release. “The Lone Star Cervical Cancer Elimination Plan gives us a shared roadmap to vaccinate more of our children, screen more of our women and make sure every abnormal result leads to care. With innovations like HPV self-collection and the commitment of partners across the state, elimination is within reach.”

About 40 other hospitals, health care organizations and companies join MD Anderson in the coalition that launched the Lonestar Plan. Those based in Houston include Houston Methodist, Rice University, UTHealth Houston, Texas Children's Hospital, Houston Health Department and others.

The CPRIT also announced its Texans Conquer Cancer Awards and its CPRIT Champion awards during the Innovations Conference this week. Several are based in Houston, including:

  • Zhiqiang An, co-founder of CrossBridge Bio, Director of the Texas Therapeutics Institute, and Vice President of Drug Discovery at the University of Texas Health Science Center at Houston
  • Dr. Abbey Berenson, Director of the UTMB Center for Interdisciplinary Research in Women's Health Care
  • Dr. Michael Taylor, Chair of Pediatric Neuro-Oncology at Texas Children's Cancer and Hematology Center and Director of Texas Children's Pediatric Brain Tumor Research Program

To date, the CPRIT has awarded more than $4.2 billion in grants to fight cancer in the state. Over the summer, it awarded four $2 million grants to institutions in Houston and Bryan for the creation or expansion of “core” cancer research facilities.

Texas Medical Center Innovation recently announced that its $2 million grant would renew its Accelerator for Cancer Therapeutics for five years. Read more from TMCi about the renewal here.

The Texas Medical Center's ACT program is making sure the most-promising cancer research makes it to its life-saving commercialization stage. Photo via tmc.edu

Houston program buoys promising cancer research with live-saving innovation

act-ing now

How do you bring promising cancer research to the masses? TMC Innovation's Accelerator for Cancer Therapeutics was established with that question in mind.

Funded by a $5 million grant from CPRIT, or the Cancer Prevention and Research Institute of Texas, in 2019 and in collaboration with the Gulf Coast Consortia and the University of Texas Medical Branch, the first cohort began their intensive work in 2021. The deadline to join the next cohort is October 13.

Since its inception, ACT has seen the forming of 19 companies — two of which have been awarded CPRIT seed grants, along with four in contention for one this year — as well as $92 million in dilutive funding and $10 million in non-dilutive funding.

“We’ve recruited investigators and companies from the breadth and width of the state of Texas, so all the way from Lubbock to Galveston from Dallas to the Rio Grande Valley,” Ahmed AlRawi, program manager, tells InnovationMap. “We've had an amazing set of investigators who have gone through the program — 56 teams to be precise.”

AlRawi says that the first pillar of the program is education. To that end, the cohort works with entrepreneurs in residence like Michael Torres. Best known as the co-founder of ReCode Therapeutics, Torres says that one of his greatest passions lies in translating science into medicines. ReCode is a genetic medicines company that is currently clinical-stage. It’s raised more than $300 million in the last two years, certainly something to which scientist-entrepreneurs earlier in their careers would aspire.

A longtime resident of Dallas, Torres moved his family to Houston last year, calling it “the place to be for cancer startups in Texas.”

Initially, says Torres, Houston wasn’t on his radar. But thanks to a call from ACT external advisor Dan Hargrove, Torres realized that the city might be a fit for him and his goals.

“I wanted to find a project that I could help support, sort of take my experience as a cofounder and help guide the next great startup within the ecosystem,” he says.

Torres and AlRawi agree that the biggest successes to come out of ACT so far include March Biosciences, a company from the first cohort, which is focused on developing CAR-T cell strategies to help combat hematological cancers; CPRIT fundee, OmniNano Pharmaceuticals, which uses patented nanotechnology to co-deliver a pair of therapeutical agents to solid tumors; and the latest, CrossBridge Bio.

Part of the most recent cohort, Torres has joined Drs. Kyoji Tsuchikama and Zhiqiang An as the last company’s CEO. To that end, he’s partnered with the world-class researchers out of UT Health Houston to build a next-generation antibody drug conjugate company that he believes will produce “better and safer and more effective drugs than what's currently on the market today.”

All the more reason that Torres he’s glad to have moved to Houston at what he calls “a really exciting time.” He’s thankful for the Texas Medical Center and the relationships it fosters. “We're all sort of aligning on creating a sustainable biotech ecosystem,” he says. And the next big cancer fighting company may well emerge from ACT.

Six Houston inventors have been recognized with the highest professional distinction for inventors within academia. Photo via Pexels

6 Houston-area inventors named fellows in prestigious program

best in class

The National Academy of Inventors has announced its annual set of NAI Fellows — and six Houstonians make the list of the 164 honorees from 116 research institutions worldwide.

The NAI Fellows Program honors academic inventors "who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society," according to a news release. The appointment is the highest professional distinction for inventors within academia.

The six Houstonians on the list join a group that hold more than 48,000 U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs, per the release. Additionally, $3 trillion in revenue has been generated based on NAI Fellow discoveries.

These are the scientists from Houston organizations:

    • Zhiqiang An, University of Texas Health Science Center at Houston: An is the director of the Texas Therapeutics Institute, a drug discovery program operated by the John P. and Kathrine G. McGovern Medical School at Houston. He's also a professor of molecular medicine and holder of the Robert A. Welch Distinguished University Chair in Chemistry at UTHealth.
    • Alex Ignatiev, University of Houston: Ignatiev served as director of two NASA-supported research and technology development centers at the University of Houston and as Lillie Cranz and Hugh Roy Cullen Professor of Physics, Chemistry, and Electrical and Computer Engineering.
    • David Jaffray, University of Texas MD Anderson Cancer Center: Jaffray was appointed MD Anderson's first-ever chief technology and digital officer in 2019. He oversees MD Anderson’s Information Services division and Information Security department and is a professor of Radiation Physics with a joint appointment in Imaging Physics.
    • Pei-Yong Shi,The University of Texas Medical Branch: Pei-Yong Shi is a professor and John Sealy Distinguished Chair in Innovations in Molecular Biology Department of Biochemistry & Molecular Biology;. He's also the Vice Chair for Innovation and Commercialization.
    • Ganesh Thakur, University of Houston: Thakur is a pioneer in carbon capture, utilization and storage and has a patent on forecasting performance of water injection and enhanced oil recovery. His team is continuing to push the research envelope for CCUS employing world-class lab research, simulation, machine learning and artificial intelligence.
    • Darren Woodside, Texas Heart Institute: Woodside is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. His research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases.
    Ten other Texas-based innovators made the list, including:
    • Sanjay Banerjee, The University of Texas at Austin
    • Thomas Boland, The University of Texas at El Paso
    • Joan Brennecke, The University of Texas at Austin
    • Gerard Cote, Texas A&M University
    • Ananth Dodabalapur, The University of Texas at Austin
    • Holloway (Holly) H. Frost Jr., The University of Texas at Arlington
    • James E. Hubbard, Texas A&M University
    • Yi Lu, University of Texas at Austin
    • Samuel Prien, Texas Tech University
    • Earl E. Swartzlander Jr., The University of Texas at Austin
    This year's class will be inducted at the Fellows Induction Ceremony at the 11th Annual Meeting of the National Academy of Inventors in June in Phoenix, Arizona.

    "The caliber of this year's class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields," says Paul R. Sanberg, president of NAI's board of directors, in the release. "The breadth and scope of their discovery is truly staggering. I'm excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide."

    Ad Placement 300x100
    Ad Placement 300x600

    CultureMap Emails are Awesome

    MD Anderson receives $10M gift to launch pancreatic cancer program

    med funding

    The University of Texas MD Anderson Cancer Center will be getting a significant boost in the fight against pancreatic cancer thanks to a recent gift from longtime supporters Zelma and William Reid. The medical system announced this month that a $10 million donation would help it establish a new Pancreatic Cancer High-Risk Interception Program.

    “Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

    Pancreatic cancer is one of the most deadly types of cancer. Despite being relatively rare, it ranks third in total deaths from cancer in the United States. Less than 10 percent of patients diagnosed with pancreatic cancer are still alive five years later.

    Dr. Florencia McAllister, William Reid, Dr. Michael P. Kim, Zelma Reid, Dr. Manoop S. Bhutani, and Dr. Matthew H.G. Katz. Photo courtesy MD Anderson

    The problem is often detection. The pancreas is located deep in the upper abdomen among many other organs, which can make spotting tumors difficult. Some blood tests can indicate pancreatic cancer, but it is usually not diagnosed until it spreads.

    The new Pancreatic Cancer High-Risk Interception Program hopes to assemble new diagnostic techniques and patient screening tools to increase early detection. MD Anderson’s Dr. Michael P. Kim, associate professor of surgical oncology; Dr. Manoop S. Bhutani, professor of gastroenterology and hepatology; and Dr. Florencia McAllister, professor of gastrointestinal medical oncology and genetics, will lead the new program.

    The team will rely on advanced imaging, molecular diagnostics, AI-driven assessment, and DNA testing to both create an at-risk patient population profile and hopefully help detect the cancer in its earliest stages. For instance, some of these tools will be able to monitor pancreatic cysts without invasive surgery.

    “The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim added in the release. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

    Axiom Space inks partnership to grow semiconductor crystals in orbit

    space deal

    Down in Webster, Texas, and high above the Earth, Axiom Space and Kansas-based Nitride Global Inc. will grow the next generation of semiconductor crystals in microgravity thanks to a new memorandum of understanding (MOU) signed earlier this month.

    “Signing this MOU with Nitride Global reflects the growing commercial interest in producing advanced semiconductor materials in space,” Lucie Low, chief science officer for Axiom Space, said in a news release. “Their leadership in aluminium nitride (AlN) crystal growth and advanced packaging technologies, combined with Axiom Space’s capabilities in orbital infrastructure and mission integration, position us to demonstrate real commercial value in low-Earth orbit (LEO).”

    This latest partnership builds on existing collaboration between Axiom and NitrideGlobal and NASA Ames Research Center.

    Aluminium nitride crystals are part of the cutting-edge generation of semiconductors essential to emerging high-voltage transistors and also used in various medical technologies. Because of their high thermal stability, they can be used in a variety of environments and applications that have revolutionized everything from electric cars to the grids the cars run on.

    However, the crystals are challenging to grow on Earth and face defects and size limitations due to gravity. Growing them in space can enhance their performance, according to NitrideGlobal. Microgravity allows them to grow more uniformly and with fewer defects, potentially resulting in larger, purer and more reliable crystals.

    That’s where Axiom Space comes in. The company is developing Axiom Station, a successor to the International Space Station, where new research and manufacturing can be carried out.

    “This MOU marks a pivotal milestone in our close partnership with Axiom Space that started as part of the NASA Small Business Innovation Research (SBIR) for AlN growth in space and is now expanding to usher the development of an innovation ecosystem,” Mahyar Khosravi, CEO of Nitride Global Inc., added in the release. “With Axiom Space’s leadership in the in-space manufacturing sector, this partnership will aim to deliver a platform for commercially viable manufacturing of [ultrawide bandgap materials] that will enable the next generation of semiconductor & microelectronics for terrestrial and planetary exploration uses.”

    Houston's IAH lands on list of 15 most expensive U.S. airports

    Travel Woes

    Hold on to those carry-on bags: George Bush Intercontinental Airport is checking in as one of the 15 most expensive airports in the U.S., a new study has revealed.

    The analysis from digital commerce and marketing platform ConsumerVoice.org compared the average domestic flight costs at the 50 largest U.S. airports, ranking them from highest to lowest. Flight price data was sourced from the U.S. Department of Transportation’s Bureau of Transportation Statistics (BTS) during the first and second quarters of 2026 and compared with the same period in 2025.

    Washington Dulles International Airport in Virginia tops the list as the priciest major airport in the U.S, with domestic flights at IAD costing $534.34 on average. Charlotte Douglas International Airport in North Carolina comes in second place with an average fare cost of $527.79.

    IAH lands at No. 13 nationwide, and it's the second most expensive in Texas, the findings show. The typical domestic flight from IAH costs $482.02, and they aren't getting any cheaper. Flights out of IAH are nine percent more expensive than they were a year ago, the report found. The average domestic flight cost $37.80 less in 2025.

    Houstonians not only need to be prepared to spend a little extra money when booking their tickets; they'll also need to pack their patience, as IAH also ranks among the worst airports for flight delays and cancellations.

    Travelers on a budget can save more on flights out of William P. Hobby Airport, if they're willing to make the drive. Travelers can save about 13 percent on their flights by flying through HOU instead of IAH, but there are other costs to take into consideration.

    "Ground transportation, gas, and parking can eat into the difference, so factor these in when choosing the most economical departure airport," the report said.

    HOU ranked as the No. 31 most expensive airport on the list with domestic flights coming in at $417.78 on average. Average fares at HOU are also nine percent more expensive than they were last year.

    The top 10 priciest major airports in the U.S. are:

    • No. 1 – Washington Dulles International Airport
    • No. 2 – Charlotte Douglas International Airport
    • No. 3 – Detroit metro Wayne County Airport
    • No. 4 – Salt Lake City International
    • No. 5 – Minneapolis-St. Paul International
    • No. 6 – San Francisco International
    • No. 7 – John F. Kennedy International
    • No. 8 – Newark Liberty International
    • No. 9 – Dallas/Fort Worth International
    • No. 10 – Hartsfield-Jackson Atlanta International
    ---

    This article originally appeared on CultureMap.com.